(14R)-14-hydroxy-4,14-retroretinol (14-HRR)
|
|
- Leona Sanders
- 5 years ago
- Views:
Transcription
1 Table S7 Atypical retinoids and retinoid-related molecules (RRMs) ame Chemical structure of the ligand(s) Mechanism of action and uses References Anhydroretinol (AR) Modulators of c-raf kinase 1-3 Blocks B lymphocyte proliferation as well as activation of resting T lymphocytes (14R)-14-hydroxy-4,14-retroretinol (14-RR) xidative stress and cell death 14 4 Growth-promoting properties in B-cells 4,5 4-ydroxyphenylretinamide (4-PR); Fenretinide Reduction of recurrent breast cancer in pre-menopausal women Patients who are undergoing surgical resection for recurrent glioblastoma multiforme (phase II) Recurrent hormone-naive prostate cancer (phase II) hormone-refractory prostate cancer varian epithelial or primary peritoneal cancer (phase II) ATURE REVIEWS DRUG DISCVERY ature Publishing Group
2 4-amino-2-(butyrylamino)phenylretinamide (ABP or CBG41) 2 resistant neuroblastoma (phase II) Patients with advanced solid tumors (phase I) Bladder cancer (phase III) CT116 colon cancer and other cell lines 6 Mofarotene (Ro ) Aminoarotinoid Regression of chemicallyinduced mammary tumors in rats More potent (70x) than ATRA in neoplastic cells derived from pancreatic and gastrointestinal tissues 7 8 Potent apoptotic actvity in 2 MDR cells 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2- naphthalenecarboxylic acid (AP/CD437) C Apoptotic activity in preclinical models of leukemia and carcinoma both in vitro and in vivo. Apoptogenic activity in retinoid-resistant cells and in 9-11 ATURE REVIEWS DRUG DISCVERY ature Publishing Group
3 RARγ-negative cells ST1926 (APC) 3-Cl-APC 3-A-APC Cl C Similar to AP Potent apoptotic activity associated with an early genotoxic stress C C Activates F-kB with apoptosis in a number of cancer cells Antagonizes cell-apoptotic events, but not antiproliferative events induced by AP MX781 (CD2674) Ac C Antiproliferative activity Induction of apoptosis via caspase 2 Inhibiton of IkB kinase 15 ATURE REVIEWS DRUG DISCVERY ature Publishing Group
4 AG193,918 C Inhibition of pancreatic cancer cell proliferation via supression of cell cycle regulatory protein function and induction of caspaseassociated apoptosis 16 Acyclic Retinoid (AR, IK333, polyprenoic acid) C 2 Chemoprevention of hepatocellular carcinoma 17 SetA2 S S 2 Apoptosis in squamous carcinoma cells (receptor independent/mitochondria dependent pathway) 18 References 1. Korichneva, I. & ammerling, U. F-actin as a functional target for retro-retinoids: a potential role in anhydroretinol-triggered cell death. J Cell Sci 112 ( Pt 15), (1999). 2. Chen, Y. et al. Anhydroretinol induces oxidative stress and cell death. Cancer Res 59, (1999). 3. oyos, B. et al. Activation of c-raf kinase by ultraviolet light. Regulation by retinoids. J Biol Chem 277, (2002). 4. 'Connell, M. J. et al. Retro-retinoids in regulated cell growth and death. J Exp Med 184, (1996). 5. Buck, J. et al. Anhydroretinol: a naturally occurring inhibitor of lymphocyte physiology. J Exp Med 178, (1993). 6. Um, S.-J. et al. ovel retinoic acid derivative ABP has potent inhibitory activity on cell growth and apoptosis in cancer cells. Int. J. Cancer 107, (2003). ATURE REVIEWS DRUG DISCVERY ature Publishing Group
5 7. Kaufmann, F. et al. Anti-proliferative effects of the arotinoid Ro on human cancer cells in vitro. Br. J. Cancer 67, (1993). 8. Simoni, D. et al. Programmed Cell Death (PCD) Associated with the Stilbene Motif of Arotinoids: Discovery of ovel Apoptotic Inducer Agents Possessing Activity on Multidrug Resistant Tumor Cells. Bioorg. Med. Chem. Lett. 10, (2000). 9. su, C. A. et al. Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway. Blood 89, (1997). 10. Shao, Z. M. et al. p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. ncogene 11, (1995). 11. Keedwell, R. G. et al. A retinoid-related molecule that does not bind to classical retinoid receptors potently induces apoptosis in human prostate cancer cells through rapid caspase activation. Cancer Res 64, (2004). 12. Cincinetti, R. et al. A ovel Atypical Retinoid Endowed with Proapoptotic and Antitumor Activity. J. Med. Chem. 46, (2003). 13. Farhana, L. et al. Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-kappab activation. Cancer Res 65, (2005). 14. Dawson, M. I. et al. Antagonist analogue of 6-[3'-(1-adamantyl)-4'-hydroxyphenyl]-2-naphthalenecarboxylic acid (AP) family of apoptosis inducers that effectively blocks AP-induced apoptosis but not cell-cycle arrest. J Med Chem 47, (2004). 15. Bayon, Y. et al. Inhibition of IkappaB kinase by a new class of retinoid-related anticancer agents that induce apoptosis. Mol Cell Biol 23, (2003). 16. Keedwell, R. G. et al. A Retinoid-Related Molecule that Does not Bind to Classical Retinoid Receptors Potently Induces Apoptosis in uman Prostate Cancer Cells through Rapid Caspase Activation. Cancer Res. 64, (2004). 17. Kojima, S. et al. Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (review). Int J ncol 24, (2004). 18. Chun, K.. et al. The synthetic heteroarotinoid SetA2 induces apoptosis in squamous carcinoma cells through a receptor-independent and mitochondria-dependent pathway. Cancer Res 63, (2003). ATURE REVIEWS DRUG DISCVERY ature Publishing Group
C-Phycocyanin (C-PC) is a n«sjfc&c- waefc-jduble phycobiliprotein. pigment isolated from Spirulina platensis. This water- soluble protein pigment is
' ^Summary C-Phycocyanin (C-PC) is a n«sjfc&c- waefc-jduble phycobiliprotein pigment isolated from Spirulina platensis. This water- soluble protein pigment is of greater importance because of its various
More informationT cell maturation. T-cell Maturation. What allows T cell maturation?
T-cell Maturation What allows T cell maturation? Direct contact with thymic epithelial cells Influence of thymic hormones Growth factors (cytokines, CSF) T cell maturation T cell progenitor DN DP SP 2ry
More informationRetinoic acid and analogs as potent inducers of differentiation and apoptosis. New promising chemopreventive and chemotherapeutic agents in oncology*
Pure Appl. Chem., Vol. 73, No. 9, pp. 1437 1444, 2001. 2001 IUPAC Retinoic acid and analogs as potent inducers of differentiation and apoptosis. New promising chemopreventive and chemotherapeutic agents
More informationBL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Overview and Mechanism of Action Dr. Leah Klapper, CSO 88 BL-8040: Novel CXCR4 Antagonist For Hematological Cancers Indications:
More informationInhibitors of Methionine Aminopeptidase-2 2 in the Treatment of Non-Hodgkin
Inhibitors of Methionine Aminopeptidase-2 2 in the Treatment of Non-Hodgkin Hodgkin s s Lymphoma Targeted Cancer Therapies William Westlin, Ph.D. Vice President, Preclinical Research Discovery of Fumagillin
More informationnumber Done by Corrected by Doctor Maha Shomaf
number 19 Done by Waseem Abo-Obeida Corrected by Abdullah Zreiqat Doctor Maha Shomaf Carcinogenesis: the molecular basis of cancer. Non-lethal genetic damage lies at the heart of carcinogenesis and leads
More informationMET Inhibitor. Merestinib, LY Drug Discovery Platform: Cancer Cell Signaling. Derived from Christensen JG, et al 1 ; Eder JP, et al.
MET Inhibitor Merestinib, LY2801653 Derived from Christensen JG, et al 1 ; Eder JP, et al. 2 Drug Discovery Platform: Cancer Cell Signaling A Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib
More informationIntroduction to pathology lecture 5/ Cell injury apoptosis. Dr H Awad 2017/18
Introduction to pathology lecture 5/ Cell injury apoptosis Dr H Awad 2017/18 Apoptosis = programmed cell death = cell suicide= individual cell death Apoptosis cell death induced by a tightly regulated
More informationBY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,
More informationCANNABIS AND CANCER. Case Presentations: Administering low-dose cannabis oil for the treatment of prostate cancer and brain cancer patients
CANNABIS AND CANCER Case Presentations: Administering low-dose cannabis oil for the treatment of prostate cancer and brain cancer patients Debra Kimless, M.D. Medical Director, ForwardGro CannMed 2017
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationNFκB What is it and What s the deal with radicals?
The Virtual Free Radical School NFκB What is it and What s the deal with radicals? Emily Ho, Ph.D Linus Pauling Institute Scientist Department of Nutrition and Food Management Oregon State University 117
More informationDrug Discovery Platform: Cancer Cell Signaling. MET Inhibitor. Merestinib, LY Christensen JG, et al1; Eder JP, et al 2
MET Inhibitor Drug Discovery Platform: Cancer Cell Signaling Christensen JG, et al1; Eder JP, et al 2 A Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus and Gemcitabine
More informationMolecular biology :- Cancer genetics lecture 11
Molecular biology :- Cancer genetics lecture 11 -We have talked about 2 group of genes that is involved in cellular transformation : proto-oncogenes and tumour suppressor genes, and it isn t enough to
More informationSTATE OF THE ART 4: Combination Immune Therapy-Chemotherapy. Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI)
STATE OF THE ART 4: Combination Immune Therapy-Chemotherapy Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI) Topics for Consideration What are the rules for integrating
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationSynthesis and Biological Evaluation of Protein Kinase D Inhibitors
Synthesis and Biological Evaluation of Protein Kinase D Inhibitors Celeste Alverez Topic Seminar October 26, 2013 Celeste Alverez @ Wipf Group 10/26/2013 1 Protein Kinase D (PKD) A novel family of serine/threonine
More informationSmall-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy
Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy Paul J. Hergenrother and Co-workers Department of Chemistry Department of Biochemistry Univeristy of Illinois-Urbana
More informationAllosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor!
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor Allosteric pocket SHP2 Phosphatase ovel allosteric Phosphatase inhibitor Evan Carder Wipf
More informationCancer preventive effects of lactic acid bacteria
TALAB Symposium 2007. 11. 9. National Taiwan Univ. Cancer preventive effects of lactic acid bacteria Hyong Joo Lee Seoul National University 1 Total deaths from cancer and heart disease J. Natl. Cancer
More informationFigure 8.1: Principle reaction behind DPPH assay Unnati Shah Institute of Pharmacy, Nirma University-Ph.D. thesis 136
8. Antioxidant and DNA fragmentation assay of bioactives of S. racemosa 8.1. Instrument Instruments used in the study were Gel electrophoresis assembly (Genei, India), UV spectrophotometer (Shimadzu, Japan)
More informationIntroduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.
Cancer Biology Chapter 18 Eric J. Hall., Amato Giaccia, Radiobiology for the Radiologist Introduction Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell death)
More informationDevelopment status of ONO-4538(nivolumab)1
Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1
More informationContents. Preface XV Acknowledgments XXI List of Abbreviations XXIII About the Companion Website XXIX
Contents Preface XV Acknowledgments XXI List of Abbreviations XXIII About the Companion Website XXIX 1 General Aspects of Signal Transduction and Cancer Therapy 1 1.1 General Principles of Signal Transduction
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationCrosstalk between Adiponectin and IGF-IR in breast cancer. Prof. Young Jin Suh Department of Surgery The Catholic University of Korea
Crosstalk between Adiponectin and IGF-IR in breast cancer Prof. Young Jin Suh Department of Surgery The Catholic University of Korea Obesity Chronic, multifactorial disorder Hypertrophy and hyperplasia
More informationTable S1: Analysis of Notch gene rearrangements in triple negative breast cancer subtypes
Supplemental Tables Table S1: Analysis of Notch gene rearrangements in triple negative breast cancer subtypes NOTCH1 or NOTCH2 Basal Immune Luminal AR Mesenchymal Stem Like WT 27 (87%) 24 (100%) 4 (66%)
More informationDevelopment status of ONO-4538(nivolumab)1
Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1
More informationCopyright. Tocagen Inc. Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview
Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview Toca 511, delivers CD prodrug activator gene selectively to cancer cells Regulatory genes Structural RRV genes CD gene Regulatory genes Toca
More informationBREAST CANCER. Dawn Hershman, MD MS. Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center.
BREAST CANCER Dawn Hershman, MD MS Florence Irving Assistant Professor of Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center Background Breast cancer is the
More informationOne-two Punch to Deadly Pancreatic Cancer: Targeted Therapy with Mab AR9.6 and Rapamycin Analogue ACP Jan 2016
One-two Punch to Deadly Pancreatic Cancer: Targeted Therapy with Mab AR9.6 and Rapamycin Analogue ACP 2127 Jan 2016 AmrutBio Overview A subsidiary of Quest PharmaTech, a publicly traded (QPT-TSXV), Canadian
More informationTARGETED THERAPY FOR CHILDHOOD CANCERS
TARGETED THERAPY FOR CHILDHOOD CANCERS AZIZA SHAD, MD AMEY DISTINGUISHED PROFESSOR OF PEDIATRIC HEMATOLOGY ONCOLOGY, BLOOD AND MARROW TRANSPLANTATION LOMBARDI CANCER CENTER GEORGETOWN UNIVERSITY HOSPITAL
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationAntitumor Activity of CUDC-305, a Novel Oral HSP90 Inhibitor, in Solid and Hematological Tumor Xenograft Models
Antitumor Activity of CUDC-5, a Novel Oral HSP Inhibitor, in Solid and Hematological Tumor Xenograft Models Rudi Bao, MD/PhD April 1, 2 AACR 1th Annual Meeting 2 Experimental and Molecular Therapeutics
More informationAnnual Flash Report (unaudited) Fiscal Year ended March 31, 2017
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Supplemental nation Status of Development Pipeline as of May 8, 2017. Main Status of Development Pipelines (Oncology) 1. Development Status
More informationPI3K Background. The SignalRx R & D pipeline is shown below followed by a brief description of each program:
PI3K Background The phosphatidylinositol 3-kinase (PI3K) pathway is a key cell signaling node whose dysregulation commonly results in the transformation of normal cells into cancer cells. The role of PI3K
More informationCharacteristics of Cancer Stem Cells (CSCs)
GENReports: Market & Tech Analysis Characteristics of Cancer Stem Cells (CSCs) > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director Select Biosciences, Inc. enal@selectbio.us! Topic,IntroducEon,and,Scope!
More informationciap using fragment based drug discovery
Discovery of a potent dual antagonist of both XIAP and ciap using fragment based drug discovery Gianni Chessari, PhD TAT Congress 2012 Disclosures I am an employee of Astex Pharmaceuticals I will present
More informationTITLE: Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines
AD Award Number: W81XWH-05-1-0040 TITLE: Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines PRINCIPAL INVESTIGATOR: Prakash Chinnaiyan,
More informationNUTRITION, CANNABIS AND CANCER
NUTRITION, CANNABIS AND CANCER Case Presentations: Administering low-dose cannabis oil for the treatment of prostate cancer and brain cancer patients Debra Kimless, M.D. Medical Director, ForwardGro The
More informationRegarding techniques of proteomics, there is:
Molecular الحلقة biology 14 واألخيرة To put you back in the context; the discussion was about Trancriptomics (the study of transcription). The following topic will be PROTEOMICS, which is the study of
More informationAvastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 20, 2018 Avastin Description Avastin
More informationTest Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar
Link full download: http://testbankair.com/download/test-bank-for-robbins-cotran-pathologic-basis-of-disease-9th-edition-bykumar-abbas-and-aster Test Bank for Robbins and Cotran Pathologic Basis of Disease
More informationTumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
More informationLecture 8 Neoplasia II. Dr. Nabila Hamdi MD, PhD
Lecture 8 Neoplasia II Dr. Nabila Hamdi MD, PhD ILOs Understand the definition of neoplasia. List the classification of neoplasia. Describe the general characters of benign tumors. Understand the nomenclature
More informationSerum Level of Interleukin 6 & Tumor Necrosis Factor in Iraqi Breast Cancer patients MMJ 2008; 7:34 36
Serum Level of Interleukin 6 & Tumor Necrosis Factor in Iraqi Breast Cancer patients MMJ 2008; 7:34 36 R. Alsuhail Dept. of Biology, College of Science, Baghdad University Abstract: Interleukin 6 (IL 6)
More informationNUOVI BERSAGLI TERAPEUTICI NEL CANCRO PROSTATICO: TELOMERASI E SURVIVINA
NUOVI BERSAGLI TERAPEUTICI NEL CANCRO PROSTATICO: TELOMERASI E SURVIVINA Nadia Zaffaroni U.O. 10 Dipartimento di Oncologia Sperimentale e Laboratori 23 novembre 2005 Identification of critical determinants
More informationA holistic approach to targeting breast cancer part II: Micronutrient synergy. Presented by: Dr. Neha Shanker DRRI
A holistic approach to targeting breast cancer part II: Micronutrient synergy Presented by: Dr. Neha Shanker DRRI Overview of the previous webinar In the last presentation we talked about: Increase in
More informationSubject Index. Bcl-2, apoptosis regulation Bone marrow, polymorphonuclear neutrophil release 24, 26
Subject Index A1, apoptosis regulation 217, 218 Adaptive immunity, polymorphonuclear neutrophil role 31 33 Angiogenesis cancer 178 endometrium remodeling 172 HIV Tat induction mechanism 176 inflammatory
More informationTest Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar
Link full download:https://getbooksolutions.com/download/test-bank-for-robbinsand-cotran-pathologic-basis-of-disease-9th-edition-by-kumar Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th
More informationI Antonio Cilla Tatay PhD Postdoctoral researcher
ANTICARCINOGENIC EFFECT OF PHYTOSTEROLS AND/OR BETA-CRYPTOXANTHIN IN COLON CANCER CELLS I Antonio Cilla Tatay PhD Postdoctoral researcher E-mail: antonio.cilla@uv.es Nutrition and Food Science Area. Faculty
More informationDeveloping Best in Class BET Inhibitors for Oncology & AI: from Discovery to the Clinic. Kevin G. McLure, PhD EpiCongress July 2014
Developing Best in Class BET Inhibitors for Oncology & AI: from Discovery to the Clinic Kevin G. McLure, PhD EpiCongress July 2014 Zenith Epigenetics Overview Formed from Resverlogix as an independent
More informationInhibitory effect of cinnamoyl compounds against human malignant cell line
Indian Journal of Experimental Biology Vol. 44, March 2006, pp 216-220 Inhibitory effect of cinnamoyl compounds against human malignant cell line M A Indap a, S Radhika a, Leena Motiwale b & K V K Rao
More informationASCO Annual Meeting 2013, May 31 June , Chicago, IL
Phase I Study of Safety and Pharmacokinetics of GDC-0917, an Antagonist of Inhibitor of Apoptosis Proteins in Patients with Refractory Solid Tumors or Lymphoma 1 A Tolcher, 1 K Papadopoulos, 1 A Patnaik,
More informationTitle Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
More informationPhoenix Molecular Designs
Phoenix Molecular Designs DESIGNING PRECISE THERAPEUTICS TO REVOLUTIONIZE TREATMENT Our Team Dr. Sandra Dunn, Ph.D. Dr. Anna Stratford, Ph.D. Dr. Aarthi Jayanthan, Ph.D. Dr. Zaihui Zhang CEO, CSO UBC Professor
More informationIdentification of a First-In-Class PRMT5 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Mantle Cell Lymphoma
Identification of a First-In-Class PRMT5 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Mantle Cell Lymphoma Elayne Penebre, Kristy G Kuplast, Christina R Majer, P Ann Boriak-Sjodin,
More informationMetabolic Therapy with DCA (dichloroacetate) May 2014 Akbar Khan, M.D.
Metabolic Therapy with DCA (dichloroacetate) May 2014 Akbar Khan, M.D. What is DCA? a by-product of water chlorination 1 C 2 HCl 2 NaO 2 dichloroacetic acid, sodium salt small molecule, like salt and vinegar
More informationMulti-Mechanism Drugs for Oncology and Inflammation. September 2007
Multi-Mechanism Drugs for Oncology and Inflammation September 2007 1 Forward-Looking Statements Statements that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties.
More informationFusion Analysis of Solid Tumors Reveals Novel Rearrangements in Breast Carcinomas
Fusion Analysis of Solid Tumors Reveals Novel Rearrangements in Breast Carcinomas Igor Astsaturov Philip Ellis Jeff Swensen Zoran Gatalica David Arguello Sandeep Reddy Wafik El-Deiry Disclaimers Dr. Igor
More informationConvergent and Divergent Mechanisms in Aging and Cancer
Convergent and Divergent Mechanisms in Aging and Cancer Mariana S. De Lorenzo, PhD Department of Cell Biology & Molecular Medicine delorems@umdnj.edu LEARNING OBJECTIVES 1. To identify convergent and divergent
More informationNew Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일
New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 Castrate-Resistant Prostate Cancer (CRPC) Current standard therapy Androgen receptor (AR) in CRPC New systemic therapies Hormonal therapy
More informationLipoic Acid Mineral Complex
The Metabolic Role of Lipoic Acid Mineral Complex Mitochondrial Health and Metabolic Regulation of Cellular Function in Cancer and Stroke by Dr. Frank Antonawich An Introduction to Lipoic Acid Mineral
More informationDr. Bernard Huber CEO. Bio-Europe
Dr. Bernard Huber CEO Bio-Europe 2015 1 ORYX Overview ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007 and located in Baldham/Munich, Germany ORYX bridges
More informationBasis and Clinical Applications of Interferon
Interferon Therapy Basis and Clinical Applications of Interferon JMAJ 47(1): 7 12, 2004 Jiro IMANISHI Professor, Kyoto Prefectural University of Medicine Abstract: Interferon (IFN) is an antiviral substance
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationStem cells and Cancer. John Glod. December 2, 2009
Stem cells and Cancer John Glod Lehigh University Lehigh University December 2, 2009 The Tumor Microenvironment Littlepage et al Cancer Cell 2005 Cancer Stem Cells A small group of cells within the larger
More informationAvastin (bevacizumab)
Avastin (bevacizumab) Policy Number: 5.02.502 Last Review: 04/2018 Origination: 03/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Avastin
More informationNovel potential anticancer agents
Available online at www.worldscientificnews.com WSN 93 (2018) 53-62 EISSN 2392-2192 Novel potential anticancer agents Izabela Jęśkowiak*, Stanisław Ryng Department of Organic Chemistry, Faculty of Pharmacy,
More informationCancer. Questions about cancer. What is cancer? What causes unregulated cell growth? What regulates cell growth? What causes DNA damage?
Questions about cancer What is cancer? Cancer Gil McVean, Department of Statistics, Oxford What causes unregulated cell growth? What regulates cell growth? What causes DNA damage? What are the steps in
More information2019 Pharmacy Research Summer Interns (PRSI) Faculty Sponsored Projects
2019 Pharmacy Research Summer Interns (PRSI) Faculty Sponsored Projects Faculty Mentor: Dr. Serge Afeli, PhD Project Description: Bladder cancer accounts for nearly 75,000 new cases and 15,000 deaths yearly
More informationThe Metabolic Role of Lipoic Acid Mineral Complex Mitochondrial Health and Metabolic Regulation of Cellular Function in Degenerative Diseases
The Metabolic Role of Lipoic Acid Mineral Complex Mitochondrial Health and Metabolic Regulation of Cellular Function in Degenerative Diseases Dr. Frank Antonawich An Introduction to Lipoic Acid Mineral
More informationEx-Vivo heat shock protein 70-peptide-activated, autologous natural killer cells adoptive therapy: from the bench to the clinic
Ex-Vivo heat shock protein 70-peptide-activated, autologous natural killer cells adoptive therapy: from the bench to the clinic isbtc 10-13 November 2005 Valeria Milani, MD, PhD Munich Agenda 1. NK ligands
More informationHuynh Hung and Michael Pollak*
~) Pergamon Progress in Growth Factor Research, Vol. 6. Nos. 24, pp. 495--501, 1995 Copyright 1996 Elsevier Science Ltd. All rights reserved Printed in Great Britain. 0955-2235/95 $29.00 +.00 0955-2235(95)00036-4
More informationBiogen Idec Oncology Pipeline. Greg Reyes, MD, PhD SVP, Oncology Research & Development
Biogen Idec Oncology Pipeline Greg Reyes, MD, PhD SVP, Oncology Research & Development March 25, 2009 Biogen Idec Strategy in Lymphoma / Leukemia CLL RITUXAN NHL FC-RITUXAN GA101 RITUXAN-CVP RITUXAN-CHOP
More informationChemoprevention. Chemoprevention is the use of natural or synthetic substances to reduce the risk of
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Chemoprevention Chemoprevention
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationIntracellular signalling cascades associated with TRP channels
Gerald Thiel Intracellular signalling cascades associated with TRP channels Current state of investigations and potential applications Saarland University, Germany Campus Saarbrücken Department of Medical
More informationCancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous
Session8 Medical Genetics Cancer Genetics J avad Jamshidi F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 What is Cancer? Uncontrolled growth of cells Not all tumors
More informationMipsagargin Summary. May 2015 OTCQB: GNSZ
Mipsagargin Summary May 2015 TCQB: GNSZ 1 Safe Harbor Statement Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements that are not historical facts are forward-looking
More informationCancer genetics
Cancer genetics General information about tumorogenesis. Cancer induced by viruses. The role of somatic mutations in cancer production. Oncogenes and Tumor Suppressor Genes (TSG). Hereditary cancer. 1
More informationFor Dr. Moriyama, Dusseldorf,
Autologous Formalin-fixed Tumor Vaccine (AFTVac) For Dr. Moriyama, Dusseldorf, 2016.06.01 Background Nature Med, 1:267, 1995 Nature Med, 2:1283, 1996 Tumor-Associated Antigenic peptides (TAAs) in the formalin-fixed
More informationThe PI3K/AKT axis. Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia. Introduction
The PI3K/AKT axis Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia Introduction Phosphoinositide 3-kinase (PI3K) pathway are a family of lipid kinases discovered in 1980s. They have
More informationAvastin (bevacizumab) DRUG.00028, CG-DRUG-68
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved
More informationTITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer
AD Award Number: TITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer PRINCIPAL INVESTIGATOR: Linda A. degraffenried, Ph.D. CONTRACTING ORGANIZATION: The
More informationTUMOR M ARKERS MARKERS
TUMOR MARKERS M.Shekarabi IUMS Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers. A good
More informationMedical Facts of Aronia. Steven Saulsbury M.D. February
Medical Facts of Aronia Steven Saulsbury M.D. February 29 2014 Medical Facts Facts and medical advice change with time Medical Facts Information increasingly media and market driven Confusing and often
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More information615.2/ : , B-, AICAR (
33 615.2/.3.014.24:547.857.1.. 1,.. 1,.. 1,.. 1,.. 1,.. 1,.. 1,.. 2,.. 2,.. 2,.. 2-12 1..., 2,,, : 115478,, 24;. +7(499)612-81-92 e-mail: lantsova1979@mail.ru 24.06.2014, 08.09.2014. B-, AICAR (5- - 4-
More informationCancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation
Cancer The fundamental defect is unregulated cell division. Properties of Cancerous Cells Altered growth and proliferation Loss of growth factor dependence Loss of contact inhibition Immortalization Alterated
More informationPart-4. Cell cycle regulatory protein 5 (Cdk5) A novel target of ERK in Carb induced cell death
Part-4 Cell cycle regulatory protein 5 (Cdk5) A novel target of ERK in Carb induced cell death 95 1. Introduction The process of replicating DNA and dividing cells can be described as a series of coordinated
More informationLecture #27 Lecturer A. N. Koval
Lecture #27 Lecturer A. N. Koval Hormones Transduce Signals to Affect Homeostatic Mechanisms Koval A. (C), 2011 2 Lipophilic hormones Classifying hormones into hydrophilic and lipophilic molecules indicates
More informationCancer Chemoprevention Part 1: Retinoids and Carotenoids and Other Classic Antioxidants
Cancer Chemoprevention Part 1: Retinoids and Carotenoids and Other Classic Antioxidants Review Article [1] November 01, 1998 By Diljeet K. Singh, MD, MPH [2] and Scott M. Lippman, MD, FACP [3] Cancer chemoprevention
More informationDesign, Synthesis and Biological Screening of Focused Libraries of New Antiestrogens
Design, Synthesis and Biological Screening of Focused Libraries of New Antiestrogens Presenter: Jelena Janjic, Dipl.Pharm. Graduate student Pharmaceutical Sciences Prof. Dr. Peter Wipf s group Dr. Billy
More informationFOCiS. Lecture outline. The immunological equilibrium: balancing lymphocyte activation and control. Immunological tolerance and immune regulation -- 1
1 Immunological tolerance and immune regulation -- 1 Abul K. Abbas UCSF FOCiS 2 Lecture outline Principles of immune regulation Self-tolerance; mechanisms of central and peripheral tolerance Inhibitory
More informationSOMATOSTATIN RECEPTORS IN HEPATOCELLULAR CARCINOMA. Marie LEQUOY Saint-Antoine Hospital, Department of Hepatology, Paris, France
SOMATOSTATIN RECEPTORS IN HEPATOCELLULAR CARCINOMA Marie LEQUOY Saint-Antoine Hospital, Department of Hepatology, Paris, France Somatostatin : SST Somatostatin (SST) protein : 2 active forms (alternative
More informationOMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors
OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors Jakob Dupont MD MA CMO, SVP: OncoMed Pharmaceuticals Adjunct Clinical Faculty: Stanford University
More informationBerberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through mir-93/ PTEN/Akt Signaling Pathway
Chen Accepted: et al.: February Berberine 24, Sensitizes 2015 Ovarian Cancer Cells to Cisplatin www.karger.com/cpb 956 1421-9778/15/0363-0956$39.50/0 Original Paper This is an Open Access article licensed
More information